Consequently, such markers have to be expressed on both, the VSMCs (being exposed to the blood after endothelial removal) and the activated, regenerating endothelial cells (ECs), which start covering the vascular wound ( Figure I in the online-only Data Supplement). Finally, the markers should show a low luminal exposure under physiological conditions.
Ultrasound imaging using targeted microbubbles (MBs) can potentially provide valuable insights into the presence of prominent inflammation surface markers during the various states of endothelial regeneration, allowing the personalization of anti-inflammatory therapy in dosage, medication period, and combination.
In this study, we propose vascular cell adhesion molecule (VCAM)-1 as an ultrasound imaging biomarker of endothelial healing in big vessels, such as carotid arteries. VCAM-1 is expressed by activated VSMCs and it is accessible for intravascular targeting after arterial denudation, whereas replicating ECs express VCAM-1 during endothelial reconstruction until regeneration 10, 11 (Figure I in the online-only Data Supplement). We, therefore, used VCAM-1-targeted MBs (MB VCAM-1 ) and molecular ultrasound to monitor arterial endothelial recovery, and validated the results using twophoton laser scanning microscopy (TPLSM) as a deep-tissue imaging modality. TPLSM was applied for the characterization of VCAM-1 expression, MB binding, and morphological changes in the arterial lumen on cellular and subcellular levels. Our data provide strong evidence that MB VCAM-1 are suitable for noninvasive molecular ultrasound monitoring of vascular healing in a murine model of endothelial denudation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Ex Vivo Whole Mount Artery TPLSM Imaging of Wire-Injured Carotids
Before endothelial denudation, animals were fed a high cholesterol diet for either 1 week (short-term diet) or 12 weeks (long-term diet). The majority of experiments were conducted on animals with a short-term diet to induce hyperlipidemia, to validate MB VCAM-1 -binding specificity and efficiency under postinterventional conditions. The long-term diet group was Three-dimensional rendering of denudated carotid arteries of mice from the short-term atherogenic diet group and quantification of endothelial recovery. Using platelet/endothelial cell adhesion molecule (PECAM)-1 as a marker for endothelial cells and vascular cell adhesion molecule (VCAM)-1 for endothelial regeneration, z-stack images were rendered to better illustrate the extent of regeneration and inflammation. A, The degree of endothelial regeneration is depicted starting from 1 day until 14 days post denudation. B, Graph reporting the percentage of endothelial coverage in carotid arteries before and after denudation, compared with control vessels. While directly after denudation, almost the entire vessel surface was removed, 94% of the endothelial surface coverage was reconstituted after 14 days. C, To illustrate the availability of endothelial VCAM-1, the Manders coefficient for VCAM-1 colocalization with PECAM-1 for all time points was calculated. Scale bar, 25 μm.
by guest on June 30, 2017 http://atvb.ahajournals.org/ Downloaded from introduced to investigate the effect of high cholesterol diet on the rate of endothelial regeneration after plaque removal by wire injury and the potential of molecular ultrasound to distinguish between both the conditions. First, the VCAM-1 expression pattern and the degree of endothelial regeneration were studied in mice on short-term diet after endothelial denudation. We stained ex vivo mounted carotid arteries for platelet/EC adhesion molecule (PECAM)-1, VCAM-1, and nuclei, and analyzed marker expression using TPLSM at the 4 different time points (1, 3, 7 , and 14 days: Figure 1A ; Figure  II in the online-only Data Supplement). Three-dimensional (3D) reconstruction of the vessel wall and quantification of the endothelial regeneration showed only EC debris at 1 day, and an endothelial coverage of 18% after 3 days, 80% after 7 days, and 94% after 14 days, respectively ( Figure 1B) .
The EC debris at day 1 was positive for VCAM-1 ( Figure  II in the online-only Data Supplement). At this time point, VCAM-1 was found to be highly expressed on VSMCs as well. The first signs of endothelial regeneration were visible 3 days after denudation, in conjunction with the highest colocalization of VCAM-1 with the endothelial marker PECAM-1, indicating pronounced ECs activation and regeneration ( Figure 1C ). In parallel, the VSMCs exposed to the vascular lumen also displayed a strong VCAM-1 expression. At later time points (7 and 14 days), ECs regeneration progressed further, showing a continuous decrease in VCAM-1 expression down to the level of noninjured controls after 14 days ( Figure 1A ; Figure II in the online-only Data Supplement). In contrast, VCAM-1 expression on VSMCs remained high even 14 days after denudation, however, these VSMCs were not luminally exposed anymore and thus not accessible to MB VCAM-1 . These findings are in line with the mean fluorescence intensity quantifications for VCAM-1 and PECAM-1 expression ( Figure III in the online-only Data Supplement).
Ultrasound Analysis of MB VCAM-1 Binding to Carotid Arteries After Wire Injury in a Flow Chamber
MB VCAM-1 binding to carotid arteries was studied in mice from the short-term diet group, 1 day after endothelial denudation. First, the efficiency and specificity of MB VCAM-1 binding to VCAM-1 under flow conditions in early denudated carotid arteries was investigated ex vivo. Approximately 9-fold higher signal decrease after MB VCAM-1 destruction in denudated carotid arteries compared with the control carotid arteries was found (P<0.001). In addition, ≈8-fold higher signal decrease after MBs destruction was obtained in denudated carotid arteries when compared with the competitive-binding group, as well as to nontargeted MBs (P<0.05 and P<0.05, respectively) indicating strong binding of MB VCAM-1 to its target ( Figure 2 ).
TPLSM Analysis of MB VCAM-1 -Binding Specificity to Carotid Arteries After Wire Injury in a Flow Chamber
Next, the extent and specificity of rhodamine-labeled MB VCAM-1 binding was validated in flow-chamber experiments using TPLSM ( Figure 3A ). Three days after endothelial denudation, carotid arteries of mice from the short-term diet group were excised and perfused under physiological flow rates (0.5 mL/min) with MB VCAM-1 . After MBs' binding and washing, the carotid arteries were stained for VCAM-1, PECAM-1, 
In vivo Evaluation of MB VCAM-1 Binding to VCAM-1 Using Ultrasound and TPLSM
Finally, MB VCAM-1 binding and detection was validated in vivo. First, in vivo MB VCAM-1 binding was tested 1 day after endothelial denudation in mice from the short-term diet group. Using contrast mode, the MBs influx after injection could be visualized ( Figure 4A ) and quantified ( Figure 4B ). After clearance of circulating MB VCAM-1 , bound MB VCAM-1 were found attached to the inner vessel wall ( Figure 4A ). Binding of significant amounts of MB VCAM-1 was further confirmed by a strong drop in ultrasound signal intensity after the application of a destruction pulse ( Figure 4C ). Competitive-binding experiments showed the specificity of MB VCAM-1 to its intended target at day 1 postsurgery in denudated carotid arteries: after blocking VCAM-1 with excess-free antibody before MB VCAM-1 injection, there was a drop in MB VCAM-1 -specific signals by 90 (±8) % ( Figure 4D ).
To verify MB binding, we performed in vivo TPLSM measurements with rhodamine-loaded 12-14 MB VCAM-1 in wire-injured carotids. After creating a surgical window for TPLSM, 15 we tracked single-bound MBs in a field of view of 500×500 μm. Immediately after injection, we monitored the influx of circulating MBs ( Figure IVA in the online-only Data Supplement), which was followed by a rapid clearance within ≈5 minutes. Although nontargeted and targeted MBs under competitive-binding conditions with free VCAM-1 antibodies did not significantly bind to the vascular wall of denudated carotid arteries (3 days after denudation), many stationary MB VCAM-1 were detected at the luminal side of the carotid artery for >6 minutes ( Figure IVB in the onlineonly Data Supplement). Even after euthanasia, excision and mounting of the carotid arteries, MB VCAM-1 were still present within the lumen (Movie I in the online-only Data Supplement).
Comparative Ultrasound Imaging Using MB VCAM-1 to Assess Endothelial Regeneration in Mice on Short-and Long-Term Atherogenic Diet In Vivo
A short-term diet of 1 week before denudation only induces hyperlipidemia without plaque development. In contrary, a long-term diet (12 weeks) leads to signs of early plaque growth. Thus, it was of interest to confirm that our molecular ultrasound approach was capable to assess vascular regeneration in both cases and to compare the course of healing. A significantly enhanced binding of MB VCAM-1 in carotid arteries could only be observed at early time points after endothelial denudation, starting immediately (1 day) and peaking at 3 days ( Figure 4D ) in both short-and long-term diet groups. In the short-term diet group, quantification showed ≈8-fold increase in ultrasound grayscale intensity difference after 1 day, and ≈15-fold increase after 3 days, compared with the control group (P<0.001 and P<0.001, respectively), whereas at day 7, only a 2-fold increase in ultrasound grayscale intensity difference compared with the control group (P>0.05) was measured. At early time points, similar results were obtained in the long-term diet group, presenting ≈9-fold increase in ultrasound grayscale intensity difference after 1 day, and ≈18-fold increase after 3 days, (P<0.05 and P<0.001, respectively). However, after 7 days still a ≈8-fold increase (P<0.001) was found in the long-term diet group, indicating a delayed endothelial recovery after wire injury, which translated into a prolonged VCAM-1 availability detected by ultrasound through MB VCAM-1 binding. Fourteen days post surgery, MB VCAM-1 binding dropped down to the level of unhandled control animals in both short-and long-term diet groups, showing that endothelial recovery can be monitored by ultrasound molecular imaging.
Immunohistology of Denudated Arteries From Long-Term Diet Group
Finally, we validated reendothelialization and VCAM-1 expression in the carotid arteries of the long-term diet group by immunohistology at 1, 3, 7, and 14 days after denudation (Figure V in the online-only Data Supplement). In control carotid arteries, VCAM-1 was found in small spots at the endothelial surface (<3% of the total area), where native plaques were developing. One day after denudation, endothelial CD31 was absent, whereas VCAM-1 was present at the luminal side and in the media. Three and 7 days after denudation, both CD31 and VCAM-1 were visible at the luminal side of the artery, whereas after 14 days VCAM-1 was only detected in the media or under the CD31-stained intima.
Discussion
The endothelial response to interventional procedures after blood flow restoration in atherosclerotic arteries is one of the most important factors determining patient recovery. The degree of endothelial damage correlates to the risk of neointima growth, platelet adhesion, and thrombosis. Thus, it precludes the success of interventional surgery, that is, slower endothelial regeneration causing a higher risk for complications. 7 After the intervention, dual antiplatelet medication and inflammatory inhibitors are applied using a standardized dosage, medication period, and combination, which is independent of the recovery rate of individual patients. However, the patient's age, general immune state, comorbidities, such as diabetes mellitus, and the different size of the plaque and injured area can strongly influence the speed of regeneration and degree of inflammation. 16, 17 Thus, there seems to be a clear need for a reliable diagnostic assessment of endothelial regeneration, as well as for the individualization of postinterventional anticoagulant and anti-inflammatory therapy.
For this purpose, as a cheap and real-time imaging modality with excellent spatial resolution, molecularly targeted ultrasound imaging may be the modality of choice. However, the selection of the target for the molecular probe must be done carefully and the target should fulfil 3 criteria, such as (1) subendothelial expression after endothelial denudation (eg, expression by luminally exposed VSMCs); (2) expression by the activated regenerating ECs; and (3) absence/low constitutive expression after reendothelialization. Previous studies have shown results indicating that some markers may have a constitutive expression level (PECAM-1, ICAM-1, P-selectin, and E-selectin), 11, 14, [18] [19] [20] other markers might either be not sufficiently expressed on activated VSMCs (PECAM-1, E-selectin, and P-selectin), 18, 21, 22 or remain to be upregulated for a prolonged period of time after complete structural recovery (PECAM-1 and ICAM-1) 19 (Table I ; Figure VI in the online-only Data Supplement).
On the basis of the current literature, VCAM-1 was chosen in this study as a target for several reasons: VCAM-1 is one of the most well-known atherosclerotic markers. 23 It has already been used for visualizing aortic atherosclerotic lesions by molecular ultrasound. [24] [25] [26] Despite its major application in atherosclerosis, VCAM-1 is also an acute inflammatory marker that is highly expressed after vascular injury, and it plays a major role in the formation of neointima and restenosis. 27 It was previously described that VCAM-1 is expressed by both ECs 28 and VSMCs 29, 30 in atherosclerotic arteries. However, binding of MB VCAM-1 to VCAM-1 is dependent on its luminal availability. On the basis of immunofluorescence quantifications and 3D renderings of the vessels, 1 day after endothelial denudation, activated medial VSMCs expressing VCAM-1 are exposed to the blood flow, presenting the only source for MB VCAM-1 binding because ECs were removed by endothelial denudation. Three days after denudation, the endothelial layer is regenerating. The activated and proliferating ECs express VCAM-1 as well, presenting an additional source for VCAM-1. Consequently, MB binding peaks because of higher receptor availability. Subsequently, VCAM-1 expression by ECs decreases with endothelial regeneration. Therefore, significant colocalization of VCAM-1 with PECAM-1 could only be observed at 3 days because of the lack of ECs after 1 day, and the absence of endothelial activation after 14 days, when endothelial coverage was close to complete. After endothelial recovery subendothelial and intimal markers, even though present and upregulated ( Figure I and II in the online-only Data Supplement), are not accessible to MBs anymore. The lack of MB VCAM-1 binding then indicates completion of the endothelial regeneration and the return of ECs toward a physiological state. Mice fed for 14 weeks with atherogenic diet showed a delay in endothelial recovery. This is not surprising because high cholesterol diet and obesity-related pathologies, such as diabetes mellitus have been reported to interfere and delay wound healing and prolong the inflammatory phase, both in animals and in patients. [31] [32] [33] Even though VCAM-1 was upregulated in the early plaque region of the control artery, significant MB VCAM-1 binding in mice with 12 weeks of diet was not detected. A possible explanation could be the limited size of the plaque area, comprising only 3% of the total endothelial surface (data not shown), which may not be sufficient to induce visible MB binding above the background noise level.
Previously, ultrasound imaging was used for the noninvasive visualization of typical in-stent restenosis after carotid stenting of the internal carotid artery in humans. [34] [35] [36] In this study, we used VCAM-1 not as a marker for targeted plaque imaging, but as an inflammation marker in the context of endothelial regeneration after intravascular procedures. The detection of delayed reendothelialization and prolonged endothelial inflammation induced by diet or drug-eluting stents is an acute issue in clinical diagnostics. The results of our study open new perspectives to the application of molecular ultrasound for monitoring vascular healing in big vessels such as carotid arteries, which are the main arteries subjected to revascularization. Potential clinical translation was further encouraged by similar results collected in a pig model (own unpublished data).
Our study has limitations. First, using MB VCAM-1 , we can monitor endothelial regeneration and coverage, but this may not be equal to complete functional endothelial recovery. Thrombogenicity and complement activation may still be given even if VCAM-1 expression levels have been normalized. Therefore, other adhesion molecules involved in leukocyte recruitment and transendothelial migration, such as P-selectin, 37, 38 should be investigated in future studies as well, to provide evidence for a functional endothelial recovery. Second, streptavidin-coated MBs are not clinically translatable, nor is the use of biotinylated antibodies. However, targeting peptides and antibodies can also be coupled using nonimmunogenic linkers. This was recently demonstrated with clinically applicable poly-n-butylcyanoacrylate MBs based on a peptide ligand for specific imaging of E-selectin expression in tumor blood vessels, 39 as well as with angiogenesis-specific VEGFR 2 -MBs in molecular imaging of breast and prostate cancer, 40, 41 and with P-and E-selectin-targeted MBs in inflammatory bowel disease 42 and myocardial infarction. 43 Following these examples of clinically translatable molecular ultrasound contrast agents, the generation of a MB this diagnostic method can only be applied in case of polymerbased stents and after endarterectomy.
In conclusion, we demonstrate that noninvasive molecular ultrasound monitoring of vascular healing after intravascular procedures is possible through luminal exposure of VCAM-1 when using VCAM-1-targeted MBs as intravascular molecular probes. Therefore, molecular ultrasound imaging may become an important diagnostic tool supporting the development of adequate therapeutic strategies to reduce complications and to personalize anticoagulant and anti-inflammatory therapy after stent implantation or endarterectomy in carotid arteries for cerebral revascularization.
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Synthesis of poly n-butylcyanoacrylate target-specific MBs
Rhodamine loaded poly-n-butylcyanoacrylate (PBCA)-stabilized, air-filled MBs were prepared and functionalized as previously described 1, 2 . 1x10 7 streptavidin-coated MBs in HEPES/Triton buffer (pH 7.0) were mixed with 5 µg of biotinylated anti-VCAM-1 antibody (clone 429, eBioscience) and incubated at room temperature for 30 min. Conjugated MBs were separated from excess antibody by 30 min flotation and re-suspended in 50 µL HEPES/Triton buffer.
Atherogenic murine model of restenosis
Animal experiments were approved by local authorities and complied with the European Convention of Animal Protection law. Two similar animal models of accelerated atherosclerosis were used in this study: 1) eight-week old ApoE -/-mice were fed an atherogenic diet (Altromin, Germany) for 1 week before and 2 weeks after the carotid injury (named short-term diet group); 2) mice were fed an atherogenic diet for 12 weeks before and 2 weeks after the arterial denudation (named long-term diet group). The arterial injury was performed using a coated guide wire as previously described 3 . A total number of 122 animals were used for this study, consisting of n=29 for ex vivo TPLSM studies, n=15 for immunohistology, n=12 for ex vivo US, n=25 for in vivo TPLSM and n=41 for in vivo US. Following the wireinjury procedure, VCAM-1 expression was measured at different time points (1, 3, 7, 14 days post-injury).
Operative procedures for flow-chamber experiments
For each time point (1, 3, 7, 14 d) after arterial injury, mice were killed by intraperitoneal (i.p.) overdose injection of 400 mg/ml ketamine and 40 mg/ml xylazine. In addition, a terminal blood collection was performed via intracardiac puncture. The common carotid arteries (6-7 mm) were excised by restricted handling of both ends of the blood vessel to exclude luminal alterations. In order to avoid air bubbles within the lumen and tissue dryness, the blood vessels were preserved at 4°C in 1x Hanks Balanced Salt Solution (HBSS, pH 7.4, Life Technologies) during ex vivo imaging preparations. Each excised carotid artery was mounted in a customized flow chamber and then filled with HBSS (37°C) as previously described 4 . For the US flow chamber experiments, we used a 7 cm deep flow-chamber to ensure US-waves propagation and the carotid artery was brought into the field of view by immersing the scan-head into the liquid. To mimic physiological conditions inside the mounted carotid arteries, fresh blood collected from healthy volunteers was anti-coagulated with heparin (10 U/ml) -EDTA (1.2 -2 mg EDTA/ml) and infused through the carotids preserving the physiological flow direction. Subsequently, MBs suspended in whole blood, were infused for 10 min, followed by a 4 min washing step using human blood and a second washing step using HBSS.
Ex vivo whole mount artery TPLSM imaging of wire-injured carotids
Animals (n=20) were operated as described above. At 1, 3, 7 and 14 d post-surgery, mice (n=5, for each time point) were sacrificed via overdose i.p. injection of anesthetics. After mounting and flushing the carotids, cell nuclei (SYTO 41), endothelial PECAM-1 (CD31), and VCAM-1 (CD106) were stained by an one-step incubation. 400 μl of HBSS containing anti-CD31 Oregon Green 488 (2.5 μg/mL), anti-CD106 Alexa Fluor 568 (2.5 μg/mL), and SYTO 41 (5 nM) were used to flush the carotid artery. Incubation was performed at transluminal pressure of 80 mmHg for 1 h. After flushing the artery with HBSS, imaging was performed using an Olympus FV1000MPE multiphoton microscopy system (Mai Tai DeepSee pulsed Ti:Sapphire laser with 140 fs pulse width at an excitation wavelength of 800 nm). A 25x water dipping objective with numeric aperture (NA) of 1.05, working distance (WD) of 2 mm, and with optical zoom capability was used. Three internal photon multiplier tubes were used to detect the fluorescence signals and filters were adjusted to the corresponding spectra: 418-468 nm for SYTO 41, 495-540 nm for elastin autofluorescence and CD31, and 595-650 nm for CD106. TPLSM images were analyzed using Image-Pro Analyzer 7.0 software (Media Cybernetis, Inc.) and Imaris software (Bitplane).
Flow chamber experiments on the binding of MB VCAM-1 to carotid arteries after wire-injury using molecular US
High-resolution imaging of the excised carotid arteries 1 d after the arterial denudation (n=12) was performed with a linear high-frequency transducer (55 MHz, mechanical index 0.9, peak negative pressure 6.7 MPa, axial resolution 30 μm, lateral resolution 70 μm, focal length 4.5 mm, depth of field 1.4 mm, field of view 10.9 mm) connected to a small animal US imaging system (Vevo 770, VisualSonics Inc) using a long-axis imaging plane. Measurements were performed using the contrast mode, which makes use of the enhanced scattering of MBs at low US energies (4% power, mechanical index 0.04) to distinguish them from tissue response. Ten minutes after MBs infusion, a visible steady-state confirmed a homogeneous MBs distribution in the circulating blood before the destructive pulse (Figure 3 ). After 10 min of continuous flow, the MBs-blood mixture was removed from the circuit by two washing steps (first with blood and then with HBSS as mentioned above). For competitive binding experiments, the carotid lumen was incubated with a 20-fold higher concentration of free anti-CD106 antibody (100 μg, 2 μg/μl) for 1 h prior to MBs injection. To quantify the amount of bound MBs in the imaged area, an imaging sequence of 60 seconds (10 frames/second) was acquired. To prevent MBs destruction, the first third of the sequence recorded images at a low transducer output power of 4%. Subsequently, a destructive pulse (100% power) destroyed all MBs in the imaged area. The remaining imaging sequence was acquired at 4% power. Image analysis was performed by subtracting the mean value of grayscale intensity for several post-destructive frames (HBSS only) from the mean value of several pre-destructive frames (bound MBs). The resulting grayscale intensity difference represents the amount of signal generated by stationary MBs.
Flow chamber experiments on the binding of MB VCAM-1 to carotid arteries after wire-injury using TPLSM
Three days post wire-injury, animals (n=9) were sacrificed and the carotid arteries were mounted as described above. Prior to the binding step, the arteries were stained with OG488 labelled endothelial PECAM-1 (CD31) and SYTO 41. For competitive binding experiments, the carotid lumen was incubated with a 20x higher free anti-CD106 antibody concentration for 1 h prior to MB injection. After the infusion of MBs and washing, imaging was performed using the Olympus FV1000MPE multiphoton microscopy systems. PECAM, SYTO 41 and CD106 filter settings were selected as described above. Rhodamine-labeled MBs were imaged using an excitation wavelength of 840 nm and a spectral filter for the ranging 595-650 nm.
In vivo molecular US imaging
Mice with wire-injured carotid arteries (n=41) were investigated by molecular US imaging at different time points (1, 3, 7 and 14 d) . For catheterization and imaging the mice were anaesthetized with 1% isoflurane and placed on a heated table (Vevo Mouse Handling Table) . In vivo molecular US measurements were performed using a small animal high frequency US system (Vevo 770, VisualSonics) and a 40 MHz transducer (mechanical index 1.2, peak negative pressure 6.6 MPa, axial resolution 40 μm, lateral resolution 80 μm, focal length 6 mm, depth of field 1.5 mm, field of view 14.5 mm). MB-specific signals were acquired and color-coded overlays on Bmode images were performed using the contrast mode provided by the vendor. A dose of 2x10 7 MB VCAM-1 or MBs control (MB CTR ) was injected intravenously via the cannulated tail vein under US control (4% transmitted power, mechanical index 0.036). For competitive binding studies at 1 d after wire-injury, intravenous injection of 20-fold higher concentration of free anti-CD106 antibody (100 μg, 2 μg/μl) was applied to each mouse 10 min before MB VCAM-1 injection to block VCAM-1-binding sites. In all experiments successful MB injection was confirmed by assessing an imaging sequence of 60 seconds (10 frames/second) during the injection. Seven minutes after MB injection, molecular US imaging in contrast mode was performed as described above to measure the difference in the signal levels before and directly after the destructive pulse 5 .
In vivo TPLSM
For in vivo measurements, wire-injured ApoE -/-mice (n=25) were anesthetized using an i.p. injection of ketamine (100 mg/kg) and medetomidine (10 mg/kg). Body temperature was kept at 37°C by means of a heating pad. Then, the carotid artery was carefully exposed. For MB injections, a catheter made of a 0.28 mm polyethylene tubing adapted to a 30 G needle was inserted into the tail vein and flushed with NaCl-heparin solution. Thirty minutes before imaging 0.5 nM SYTO 13 was applied superficially on the top of the exposed carotid in order to stain the vessel adventitia for orientation within the tissue. TPLSM imaging was performed using a Leica SP5 (Leica Microsystems, Germany) with an integrated resonance scanner for high-speed imaging and a Compact
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Supplemental Video
Supplemental Video I: In vivo TPLSM of wire-injured carotid arteries, 3 d post denudation. Five minutes after MB VCAM-1 injection, stationary MBs (red), highlighted by red circles, can be observed attached to the vessel wall (green). Due to respiratory motion, the focal plane drops in and out of focus.
